MetaCap

Personalis Inc. (PSNL)

NASDAQ: PSNLHealth CareMedical SpecialitiesUSD

14.27-0.45 (-3.06%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PSNL stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.16
52-week range
4.96 – 18.89
Day range
14.23 – 14.67
Volume / Avg
3.34M / 2.49M
Beta
—

52-week range

$4.96$18.89

PSNL stock today

On Nov 20, PSNL ended the session at $14.27, shedding $0.45 (3.06%), versus the S&P 500's 3.70% decline. Shares are 24.5% below their 52-week high of $18.89, set on Aug 21, 2026 and 188.0% above the 52-week low of $4.96, in the middle of the past year's range. PSNL is up 79.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 46.7%.

Personalis has posted a net loss over the last twelve months (EPS of -$1.16), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Personalis

Company profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.

Industry
Medical Specialities
CEO
Mr. Christopher M. Hall
Headquarters
Fremont, CA
Employees
259
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Personalis generated $69.6 million in revenue, down 17.7% from fiscal 2024, its first annual decline since 2022. Personalis reported a net loss of $81.3 million, compared with a loss of $81.3 million a year earlier. Gross margin was 22.7% (down from 31.7%) and operating margin -126.4%.

Personalis annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$69.65M$84.61M$73.48M$65.05M$85.49M
Growth-17.69%+15.15%+12.97%-23.92%+8.70%
Net income$-81.27M$-81.28M$-108.30M$-113.31M$-65.23M
EPS (diluted)$-0.91$-1.37$-2.25$-2.48$-1.49

Analyst forecast

Forecast

Consensus (5 analysts)

hold

Avg. price target

$15.17+6.31%

  • Strong buy 0
  • Buy 1
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $13.00High $16.25

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.32 vs —

PSNL news

All PSNL news

Personalis peers

Health Care sector
PSNL peer companies
CompanyPrice% ChgMarket capCompare
TRUPTrupanion Inc.35.56-0.86%$1.54Bvs PSNL
LMRILumexa Imaging Holdings Inc.14.26+1.42%$1.37Bvs PSNL
ALHCAlignment Healthcare Inc.6.37-2.00%$1.33Bvs PSNL
FTREFortrea Holdings Inc.18.55-7.94%$1.79Bvs PSNL
CLOVClover Health Investments Corp. Class A3.73-1.06%$2.00Bvs PSNL
VCYTVeracyte Inc.25.13+0.36%$2.03Bvs PSNL
FRNMFreenome Inc.9.36-5.69%$1.04Bvs PSNL
CSTLCastle Biosciences Inc.32.86-1.63%$1.01Bvs PSNL

Indexes, lists and sector

Personalis stock FAQ

What is Personalis's stock price today?

PSNL last traded at $14.27 as of Nov 20, 4:00 PM EST, down 3.06% on the day. Prices are delayed at least 15 minutes.

Who is Personalis's CEO?

Mr. Christopher M. Hall is the chief executive officer of Personalis Inc., which has about 259 employees.

What is the PSNL 52-week high?

The 52-week high for PSNL is $18.89 and the 52-week low is $4.96. The stock is currently 24.5% below its high.

Compare PSNL